title: Chromosome 5q deletion is extremely rare in patients with myelofibrosis.
abstract: Chromosome 5q deletion can be found in rare cases of myelofibrosis (MF) but the incidence, clinical significance and response to therapies are not well studied. We retrospectively reviewed charts of 939 patients with MF and identified 8 patients [0.8%] who carried 5q deletion. Of the 8, seven had complex cytogenetic abnormalities and one had additional clone with different cytogenetic abnormality. All 8 had significant three-lineage pancytopenia. Three patients took lenalidomide and one (patient with 5q-clone) achieved long-lasting hematologic response. Two patients responded to JAK2 inhibitor therapy. MF patients with 5q deletion often have complex karyotype and poor outcome.
authors: Division of Cancer Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, United States.
authors: Koichi
authors: K
authors: Takahashi
authors: Jorge
authors: J
authors: Cortes
authors: Sherry
authors: S
authors: Pierce
authors: Lynne
authors: L
authors: Abruzzo
authors: Hagop
authors: H
authors: Kantarjian
authors: Srdan
authors: S
authors: Verstovsek
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage; D002872:Chromosome Deletion; D002895:Chromosomes, Human, Pair 5 / Q000235:genetics*; D005260:Female; D006801:Humans; D000077269:Lenalidomide; D008297:Male; D008875:Middle Aged; D055728:Primary Myelofibrosis / Q000188:drug therapy / Q000235:genetics* / Q000401:mortality; D012189:Retrospective Studies; D013792:Thalidomide / Q000008:administration & dosage / Q000031:analogs & derivatives
chemical_list: D000970:Antineoplastic Agents; D013792:Thalidomide; D000077269:Lenalidomide
references: Leukemia. 2007 Sep;21(9):1931-6
references: 17625608
references: Proc Natl Acad Sci U S A. 2007 Jul 3;104(27):11406-11
references: 17576924
references: N Engl J Med. 2010 Sep 16;363(12):1117-27
references: 20843246
references: Blood. 2009 Mar 26;113(13):2895-901
references: 18988864
references: Blood. 2002 Oct 1;100(7):2292-302
references: 12239137
references: Leuk Res. 2008 Mar;32(3):407-11
references: 17707907
references: Leuk Res. 2008 Dec;32(12):1927-30
references: 18538839
references: Haematologica. 2005 Aug;90(8):1128-32
references: 16079113
references: N Engl J Med. 2006 Oct 5;355(14):1456-65
references: 17021321
references: Cancer. 2006 May 1;106(9):1985-9
references: 16568439
references: Blood. 2007 Jul 15;110(2):719-26
references: 17420284
references: Blood. 2010 Feb 11;115(6):1131-6
references: 20008298
references: Eur J Haematol. 2009 Oct;83(4):328-33
references: 19549278
references: Blood. 2002 Jun 15;99(12):4638-41
references: 12036901
references: Br J Haematol. 1997 Jul;98(1):96-102
references: 9233570
references: Leukemia. 2007 Aug;21(8):1827-8
references: 17460705
references: N Engl J Med. 2012 Mar 1;366(9):799-807
references: 22375971
references: Blood. 2006 Aug 15;108(4):1158-64
references: 16609064
references: Blood. 2010 Jan 21;115(3):496-9
references: 19901264
references: Blood. 2006 Nov 15;108(10):3472-6
references: 16868251
references: J Clin Oncol. 2009 Oct 1;27(28):4760-6
references: 19720904
references: Blood. 2010 Mar 4;115(9):1703-8
references: 20008785
references: Blood. 2009 Apr 30;113(18):4171-8
references: 19131547
references: J Clin Oncol. 2011 Feb 1;29(4):392-7
references: 21149668
references: Nat Med. 2007 Jan;13(1):78-83
references: 17159988
references: Leukemia. 2006 Jan;20(1):168-71
references: 16270039
references: Nature. 2008 Jan 17;451(7176):335-9
references: 18202658
references: Leukemia. 2011 Jan;25(1):82-8
references: 20944670